Clinical Trial Search

Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants

Primary: Mean Change in Best-Corrected Visual Acuity at Week 12 From Baseline — 10.6; 7.8; 13.1; 9.4 letters

Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…

Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants

Primary: Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months. — 12.2 Change in ETDRS Letters — p=0.0015

Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters

Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants

Primary: Change in Macular Thickness From Baseline to 6 Weeks Postoperatively After Cataract Surgery — 252.6; 253.1 Microns

Primary: The Change in Visual Acuity (Number of ETDRS Letters). — 67.8; 71.9; 69.6; 72.9 ETDRS letters

Primary: Mean Central Macular Thickness (CMT) on Spectral Domain OCT (SDOCT) at 12 Months — 413.4 Microns

Primary: Cumulative Response Rate of 15 or More Letter Improvement — 0.101; 0.092; 0.045; 0.258 Kaplan-Meier Estimate

Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 53; 48; 38 Number of Participants

Primary: Percentage of Subjects With Vision Loss to 20/40 or Worse — 5; 3 Eyes — p=.76

Primary: Change in Excess Central Macular Thickening in the Study Eye, as Measured by Optical Coherence Tomography (OCT), at Week One Compared to Baseline — -38.60 µm

Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 60; 31 Patients

Primary: Mean Change in Best Corrected Visual Acuity — 0.3; 0.33 logMAR units

Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns

Primary: Change in Visual Acuity From Baseline to 6 Months — 7; 0 ETDRS letters

Primary: Macular Thickness at 3 Days After Intravitreous Dexamethasone — 438.44; 465.22; 368.22 µm

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 6 — 51.90; 18.60 letters

Primary: Change From Baseline in Central Subfield Foveal Thickness (CSFT) at Week 12 — -6.19; 10.26 Micrometre [μm] — p=0.3199

Primary: Frequency of Ocular Adverse Events, Systemic Adverse Events, Serious, and Treatment-emergent Non-serious Adverse Events — 10; 8; 3; 5 Participants

Primary: Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 14 ETDRS letters

Primary: Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months — -51; -60 millimeters

Primary: Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 — 44.8; 39.2; 18.1 Percentage of patients…

Primary: Percentage of Participants With Sustained Moderate Visual Loss (SMVL) Any Time Baseline Through Month 48 — 3.4; 2.2 percent of participants — p=0.724

Primary: Proportion of Baseline Central Subfield Thickness Observed at 12 Weeks — 0.65; 0.88; 0.79 Proportion of baseline retinal thickness — p=<0.001

Primary: Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye — 22.1; 18.7; 13.3 Percentage of Patients

Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters

Primary: Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye — 22.3; 18.2; 10.8 Percentage of Patients